查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
生物學名藥市場規模、佔有率和趨勢分析：按產品、按用途、按地區、按細分市場預測 2023-2030 年
市場調查報告書
商品編碼
1321333

生物學名藥市場規模、佔有率和趨勢分析：按產品、按用途、按地區、按細分市場預測 2023-2030 年

Biosimilars Market Size, Share & Trends Analysis By Product (Recombinant Glycosylated Proteins, Recombinant Non-Glycosylated Proteins), By Application (Rheumatoid Arthritis, Oncology), By Region And Segment Forecasts 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 70 Pages | 商品交期: 2-10個工作天內

價格

生物學名藥市場成長和趨勢

Grand View Research, Inc.最新報告顯示，預計2030年全球生物學名藥市場規模將達到762億美元，2023年至2030年年複合成長率為15.9%。

該市場的成長是由患者和製造商的成本效益以及癌症和貧血等慢性非傳染性疾病的患病率不斷上升推動的。世界衛生組織 (WHO) 估計，40% 的 5 歲以下兒童和 30% 的 15 至 49 歲女性患有貧血。此外，生物學名藥提供幾乎相似的結果，被認為是參考生物製劑更實惠的替代品。

由於它們幾乎相似，生物製劑生產商也被迫降低價格以與生物學名藥競爭，從而降低總體治療成本。例如，生物學名藥論壇於 2021 年 4 月發布的一份報告發現，生物學名藥的競爭加劇使生物製劑的價格平均下降了 56% 至高達 150%。此外，生物製劑擁有專利來防止生物學名藥的競爭。這些專利將生物學名藥的生產限制八到二十年，具體取決於國家法規。然而，許多挽救生命的生物製劑的專利預計將在預測期內到期，這可能會支持成長。

根據美國預算辦公室 2021 年 4 月發表的報導，美國食品藥品監督管理局 (FDA) 到 2020 年已批准了 29 種生物類似藥，其中一些尚未推向市場。事實並非如此。此外，根據學名藥和生物學名藥計劃中的報導，安進生物學名藥 Soliris 的上市時間已推遲到 2025 年。 COVID-19大流行的爆發對全球市場產生了不利影響。由於包括藥品在內的各種產品的供應鏈受到干擾，並且大多數供應商都將重點放在了應對 COVID-19 的措施上，生物學名藥的生產面臨著原料短缺的問題。

例如，約翰·霍普金斯大學彭博公共衛生學院發布的一份報告發現，由於封鎖，活性藥物成分（API）供應出現短缺，而活性藥物成分是用於製造藥品的關鍵原料。 。這些供應短缺直接影響了大流行期間生物學名藥和其他藥物的生產和供應。然而，由於需求不斷增加，多個市場參與者正在大力投資生物學名藥的研發，這可能會進一步推動市場成長。例如，提供先進生物技術解決方案的主要參與者安進公司已投資20億美元開發10種生物學名藥。

生物學名藥市場報告亮點

  • 從產品來看，重組非糖基化蛋白細分市場在 2022 年的銷售額中所佔佔有率最大，為 54.9%。
  • 另一方面，由於多種挽救生命的生物製劑的專利預計即將到期，重組糖蛋白片段預計在預測期內將以 14.9% 的年複合成長率成長最快。
  • 由於慢性病和自身免疫性疾病的患病率不斷上升，2022 年這些疾病的應用佔據了最大的銷售佔有率。
  • 由於癌症罹患率增加和重要生物製劑專利即將到期，預計腫瘤學在預測期內的年複合成長率為 17.0%。
  • 2022年，北美以40.4%的佔有率主導市場，有多個主要企業。與此同時，由於新產品的推出和醫療保健支出的增加，亞太地區預計將成為成長最快的地區，在預測期內年複合成長率為 18.4%。

目錄

第1章 調查方法和範圍

  • 市場區隔和範圍
  • 調查方法
  • 資訊採購
  • 資訊或資料分析
  • 市場形成和檢驗
  • 型號詳情
  • 二手資訊清單
  • 主要資訊清單
  • 目的

第2章 執行摘要

第3章 生物學名藥市場變量、趨勢和範圍

  • 市場體系預測
    • 母公司市場預測
    • 相關/附市場預測
  • 採用和成長預測
  • 行業價值鏈分析
    • 贖回框架
  • 市場動態
    • 市場促進因素分析
    • 市場抑制因素分析
  • 生物類似藥市場分析工具
    • 行業分析-搬運工
    • PESTEL分析

第4章 生物學名藥市場：產品評估和趨勢分析

  • 生物學名藥市場：關鍵要點
  • 生物學名藥市場：2022 年和 2030 年趨勢和市場佔有率分析
  • 重組非糖基化蛋白
    • 2018-2030 年重組非糖基化蛋白市場估算和預測
    • 人類生長激素
    • 顆粒細胞增生因子
    • 干擾素
    • 胰島素
  • 重組糖基化蛋白
    • 2018-2030年重組糖基化蛋白市場預測
    • 促紅細胞生成素
    • 單克隆抗體
    • 促卵泡素

第5章 生物學名藥市場：用途估算和趨勢分析

  • 生物學名藥市場：關鍵要點
  • 生物學名藥市場：2022 年和 2030 年趨勢和市場佔有率分析
  • 腫瘤學
  • 血液疾病
  • 生長激素缺乏症
  • 慢性和自身免疫性疾病
  • 其他

第6章 生物學名藥市場：區域估計和趨勢分析

  • 區域預測
  • 按地區分類的生物學名藥市場：主要市場要點
  • 北美
    • 2018-2030 年市場估計和預測
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 瑞典
    • 挪威
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 鯛魚
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • 沙烏地阿拉伯
    • 南非
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭形勢

  • 主要市場參與企業的最新趨勢和影響分析
  • 市場參與企業分類
    • Amgen Inc.
    • F Hoffman La Roche Ltd.
    • Sandoz International GmbH
    • Dr. Reddy's Laboratories Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Pfizer Inc.
    • Samsung Biopis
    • Biocon
    • Viatris Inc.
    • Celltrion Healthcare Co., Ltd
    • AbbVie Inc.
Product Code: 978-1-68038-916-6

Biosimilars Market Growth & Trends

The global biosimilars market size is expected to reach USD 76.2 billion by 2030, registering a CAGR of 15.9% from 2023 to 2030, according to a new report by Grand View Research, Inc. The growth of this market can be attributed to their cost effectiveness for both patients & manufacturers and the increasing prevalence of chronic & non-communicable diseases, such as cancer and anemia. According to the World Health Organizationestimates, 40% of children below five years of age, and 30% of women between the age group of 15 and 49 years are suffering from anemia. Moreover, biosimilar drugs offer almost similar results and are considered a more affordable alternative to their reference biologics.

Since they are almost similar, the producers of biologics also have to lower their prices to compete with biosimilars, which reduce the cost of the overall treatment. For instance, a report published by Biosimilars Forum in April 2021 suggests that increasing competition from biosimilars has resulted in lowering the prices of biologics by an average of 56% to up to 150%. Furthermore, biologics have patents to protect them from competing with biosimilars. These patents restrict the production of biosimilars for a period of 8 to 20 years depending on the regulations in different countries. However, patents of many lifesaving biologics are expected to expire during the forecast period, which can boost growth.

According to an article by Congressional Budget Office published in April 2021, the U.S. Food and Drugs Administration (FDA) had approved 29 biosimilar drugs by 2020, and some of them were yet to be introduced in the market. Furthermore, an article by Generics and Biosimilars Initiative suggests, the entry of Amgen's biosimilar Soliris was delayed till 2025. The outbreak of the COVID-19 pandemic had a negative impact on the global market. Since the supply chains of different products including pharmaceuticals were disrupted and most of the sources were dedicated to fighting COVID-19, the production of biosimilars experienced a shortage of raw materials.

For instance, according to a report published by Johns Hopkins Bloomberg School of Public Health, as a result of the lockdown, a shortage was observed in the supply of Active Pharmaceutical Ingredient (API), which is an important raw material used in producing drugs. These shortages directly affected the production and supply of biosimilars and other drugs during the pandemic. However, due to the increasing demand, several market players are significantly investing in the research & development of biosimilars, which can further add to the market growth. For instance, a key player offering advanced biotechnology solutions, Amgen Inc., has invested USD 2 billion in the development of 10 biosimilar medicines.

Biosimilars Market Report Highlights

  • Based on product, the recombinant non-glycosylated proteins segment accounted for the largest revenue share of 54.9% in 2022 due to a rise in the regulatory approvals for biosimilars from different governments
  • On the other hand, the recombinant glycosylated proteins segment is expected to grow at the fastest CAGR of 14.9% during the forecast period as the patents of several lifesaving biologics are expected to expire soon
  • The chronic and autoimmune disorders application segment accounted for the largest revenue share in 2022owing to the rising prevalence of these diseases
  • The oncology segment is expected to register the fastest CAGR of 17.0% during the forecast period due to the increasing prevalence of cancer and upcoming patent expiration for important biologics
  • In 2022, North America dominated the market with a share of 40.4% owing to the presence of several key players. On the other hand, Asia Pacific is anticipated to be the fastest-growing region at a CAGR of 18.4% over the forecast period due to new product launches and increasing healthcare expenditure

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Product
    • 1.1.2. Application
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline.
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives
    • 1.9.1. Objective 1
    • 1.9.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Application outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Biosimilars Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Industry Value Chain Analysis
    • 3.3.1. Reimbursement framework
  • 3.4. Market Dynamics
    • 3.4.1. Market driver analysis
      • 3.4.1.1. Increasing emphasis on cutting down healthcare expenditure
      • 3.4.1.2. Cost-effectiveness of biosimilar drugs
      • 3.4.1.3. Positive outcome in the ongoing clinical trials
      • 3.4.1.4. R&D investments are increasing.
      • 3.4.1.5. Patent expiration of biologics to boost the biosimilars market
    • 3.4.2. Market restraint analysis
      • 3.4.2.1. High manufacturing complexities and costs
      • 3.4.2.2. Presence of non-original biologics and biobetters
  • 3.5. Biosimilars Market Analysis Tools
    • 3.5.1. Industry Analysis - Porter's
      • 3.5.1.1. Supplier power
      • 3.5.1.2. Buyer power
      • 3.5.1.3. Substitution threat
      • 3.5.1.4. Threat of new entrant
      • 3.5.1.5. Competitive rivalry
    • 3.5.2. PESTEL Analysis
      • 3.5.2.1. Political landscape
      • 3.5.2.2. Technological landscape
      • 3.5.2.3. Economic landscape

Chapter 4. Biosimilars Market: Product Estimates & Trend Analysis

  • 4.1. Biosimilars Market: Key Takeaways
  • 4.2. Biosimilars Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Recombinant Non-glycosylated Proteins
    • 4.3.1. Recombinant non-glycosylated proteins market estimates and forecasts, 2018 to 2030 (USD Billion)
    • 4.3.2. Human growth hormone
      • 4.3.2.1. Human growth hormone market estimates and forecasts, 2018 to 2030 (USD Billion)
    • 4.3.3. Granulocyte colony-stimulating factor
      • 4.3.3.1. Granulocyte colony-stimulating factor market estimates and forecasts, 2018 to 2030 (USD Billion)
    • 4.3.4. Interferons
      • 4.3.4.1. Interferons market estimates and forecasts, 2018 to 2030 (USD Billion)
    • 4.3.5. Insulin
      • 4.3.5.1. Insulin market estimates and forecasts, 2018 to 2030 (USD Billion)
  • 4.4. Recombinant Glycosylated Proteins
    • 4.4.1. Recombinant glycosylated proteins market estimates and forecasts, 2018 to 2030 (USD Billion)
    • 4.4.2. Erythropoietin
      • 4.4.2.1. Erythropoietin market estimates and forecasts, 2018 to 2030 (USD Billion)
    • 4.4.3. Monoclonal antibodies
      • 4.4.3.1. Monoclonal antibodies market estimates and forecasts, 2018 to 2030 (USD Billion)
    • 4.4.4. Follitropin
      • 4.4.4.1. Follitropin market estimates and forecasts, 2018 to 2030 (USD Billion)

Chapter 5. Biosimilars Market: Application Estimates & Trend Analysis

  • 5.1. Biosimilars Market: Key Takeaways
  • 5.2. Biosimilars Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Oncology
    • 5.3.1. Oncology market estimates and forecasts, 2018 to 2030 (USD Billion)
  • 5.4. Blood Disorders
    • 5.4.1. Blood disorders market estimates and forecasts, 2018 to 2030 (USD Billion)
  • 5.5. Growth Hormonal Deficiency
    • 5.5.1. Growth hormonal deficiency market estimates and forecasts, 2018 to 2030 (USD Billion)
  • 5.6. Chronic And Autoimmune Disorders
    • 5.6.1. Chronic and autoimmune disorders market estimates and forecasts, 2018 to 2030 (USD Billion)
  • 5.7. Others
    • 5.7.1. Others market estimates and forecasts, 2018 to 2030 (USD Billion)

Chapter 6. Biosimilars Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Outlook
  • 6.2. Biosimilars Market by Region: Key Marketplace Takeaway
  • 6.3. North America
    • 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.3.2. U.S.
      • 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.3.3. Canada
      • 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.4.2. Germany
      • 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.4.3. France
      • 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.4.4. Italy
      • 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.4.5. Spain
      • 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.4.6. Sweden
      • 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.4.7. Norway
      • 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.4.8. Denmark
      • 6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.5.2. China
      • 6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.5.3. India
      • 6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.5.4. Australia
      • 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.5.5. Thailand
      • 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.5.6. South Korea
      • 6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.6.2. Mexico
      • 6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.6.3. Argentina
      • 6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
  • 6.7. MEA
    • 6.7.1. Saudi Arabia
      • 6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.7.2. South Africa
      • 6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.7.3. UAE
      • 6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.7.4. Kuwait
      • 6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Market Participant Categorization
    • 7.2.1. Amgen Inc.
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Product benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. F Hoffman La Roche Ltd.
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Product benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. Sandoz International GmbH
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Dr. Reddy's Laboratories Ltd.
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. Teva Pharmaceutical Industries Ltd.
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. Pfizer Inc.
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. Samsung Biopis
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. Biocon
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives
    • 7.2.9. Viatris Inc.
      • 7.2.9.1. Company overview
      • 7.2.9.2. Financial performance
      • 7.2.9.3. Product benchmarking
      • 7.2.9.4. Strategic initiatives
    • 7.2.10. Celltrion Healthcare Co., Ltd
      • 7.2.10.1. Company overview
      • 7.2.10.2. Financial performance
      • 7.2.10.3. Product benchmarking
      • 7.2.10.4. Strategic initiatives
    • 7.2.11. AbbVie Inc.
      • 7.2.11.1. Company overview
      • 7.2.11.2. Financial performance
      • 7.2.11.3. Product benchmarking
      • 7.2.11.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 3 North America biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 4 North America biosimilars market, by region, 2018 - 2030 (USD Billion)
  • Table 5 U.S. biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 6 U.S. biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 7 Canada biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 8 Canada biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 9 Europe biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 10 Europe biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 11 Europe biosimilars market, by region, 2018 - 2030 (USD Billion)
  • Table 12 Germany biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 13 Germany biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 14 UK biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 15 UK biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 16 France biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 17 France biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 18 Italy biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 19 Italy biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 20 Spain biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 21 Spain biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 22 Sweden biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 23 Sweden biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 24 Norway biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 25 Norway biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 26 Denmark biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 27 Denmark biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 28 Asia Pacific biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 29 Asia Pacific biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 30 Asia Pacific biosimilars market, by region, 2018 - 2030 (USD Billion)
  • Table 31 China biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 32 China biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 33 Japan biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 34 Japan biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 35 India biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 36 India biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 37 Thailand biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 38 Thailand biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 39 South Korea biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 40 South Korea biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 41 Latin America biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 42 Latin America biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 43 Latin America biosimilars market, by region, 2018 - 2030 (USD Billion)
  • Table 44 Brazil biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 45 Brazil biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 46 Mexico biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 47 Mexico biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 48 Argentina biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 49 Argentina biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 50 Middle East and Africa biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 51 Middle East and Africa biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 52 Middle East and Africa biosimilars market, by region, 2018 - 2030 (USD Billion)
  • Table 53 South Africa biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 54 South Africa biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 55 Saudi Arabia biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 56 Saudi Arabia biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 57 UAE biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 58 UAE biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 59 Kuwait biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 60 Kuwait biosimilars market, by application, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Biosimilars market outlook
  • Fig. 9 Biosimilars competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Biosimilars market driver impact
  • Fig. 15 Biosimilars market restraint impact
  • Fig. 16 Biosimilars market strategic initiatives analysis
  • Fig. 17 Biosimilars market: Product movement analysis
  • Fig. 18 Biosimilars market: Product outlook and key takeaways
  • Fig. 19 Recombinant non-glycosylated proteins market estimates and forecasts, 2018 - 2030
  • Fig. 20 Recombinant glycosylated proteins market estimates and forecasts, 2018 - 2030
  • Fig. 21 Biosimilars market: Application movement analysis
  • Fig. 22 Biosimilars market: Application outlook and key takeaways
  • Fig. 23 Oncology market estimates and forecasts, 2018 - 2030
  • Fig. 24 Blood disorders market estimates and forecasts, 2018 - 2030
  • Fig. 25 Growth hormonal deficiency market estimates and forecasts, 2018 - 2030
  • Fig. 26 Rheumatoid arthritis market estimates and forecasts, 2018 - 2030
  • Fig. 27 Chronic and autoimmune disorders market estimates and forecasts, 2018 - 2030
  • Fig. 28 Others market estimates and forecasts, 2018 - 2030
  • Fig. 29 Global biosimilars market: Regional movement analysis
  • Fig. 30 Global biosimilars market: Regional outlook and key takeaways
  • Fig. 31 North America market estimates and forecasts, 2018 - 2030
  • Fig. 32 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 33 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 34 Europe. market estimates and forecasts, 2018 - 2030
  • Fig. 35 UK market estimates and forecasts, 2018 - 2030
  • Fig. 36 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 37 France market estimates and forecasts, 2018 - 2030
  • Fig. 38 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 39 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 40 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 41 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 42 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 43 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 44 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 45 China market estimates and forecasts, 2018 - 2030
  • Fig. 46 India market estimates and forecasts, 2018 - 2030
  • Fig. 47 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 48 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 49 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 50 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 51 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 52 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 53 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 54 Middle East and Africa. market estimates and forecasts, 2018 - 2030
  • Fig. 55 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 56 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 57 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 58 Kuwait market estimates and forecasts, 2018 - 2030